This is a win for investors and could potentially be a “Big” win if new 10b5-1 regulations are tough. Too frequently CEOs and named executives skirt around insider trading rules by way of 10b5-1 plans – especially the modification of existing 10b5-1 plans. Last year we called out Moderna (MRNA) CEO Stéphane Bancel for this practice. You may read that article HERE. Watch SEC Chairman Gary Gensler speak about the topic HERE.
